Market Overview

Piper Sees "Meaningful Utility" from GW Phamaceuticals CBD, Reiterates Overweight Rating

Related GWPH
Getting The Word Out To Cannabis Users: A Chat With BudgetWeed CEO Marlon Fuller
TheStreet's David Peltier On Investing In Stocks Under $10, Picking Dividends And Apple

In a report published Friday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on GW Pharmaceuticals plc (NASDAQ: GWPH) and raised the price target from $77.00 to $97.00.

Schimmer mentioned new checks with specialists who were convinced that CBD has “meaningful utility” for seizure patients. The analyst commented that CBD and THC have been reported to benefit individuals with migraine headaches and autism.

The analyst wrote that after reviewing Dravet studies, the “finding is consistent with what we have heard from specialists, suggesting the Epidiolex Phase III studies may be overpowered, and thereby substantially improving the probability that the 'views from the field' represent a true drug effect.”

GW Pharmaceuticals closed at $57.71 on Thursday. Shares have traded as high as $64.73, up 12.16% on Friday. This has been the biggest intraday gain since January 9.

Posted-In: Joshua Schimmer Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (GWPH)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters